EUCTR2014-001353-16-BE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Written informed consent
- •2. Men or women aged 18 years and older
- •3. Systemic sclerosis, as defined by ACR/EULAR 2013 criteria
- •4. dcSSc according to the LeRoy criteria
- •5. Disease duration of = 18 months (defined as time from the first non-Raynaud’s phenomenon manifestation)
- •6. = 10 and = 22 mRSS units at the screening visit
- •7. FVC = 45% of predicted at screening
- •8. DLCO = 40% of predicted (hemoglobin-corrected) at screening
- •9. Negative serum pregnancy test in a woman of childbearing potential at the screening visit
- •10. Women of childbearing potential must agree to use adequate contraception when sexually active. Adequate contraception” is defined as any combination of at least 2 effective methods of birth control, of which at least 1 is a physical barrier (e.g. condom with hormonal contraception like implants or combined oral contraceptives, condom with intrauterine devices). This applies since signing of the informed consent form until 30 (+5) days after the last study drug administration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •1. Limited cutaneous SSc at screening
- •2. Major surgery (including joint surgery) within 8 weeks prior to screening
- •3. Hepatic insufficiency classified as Child-Pugh C
- •Patients with isolated AST or ALT >3xULN or bilirubin >2xULN can be included in the trial under the condition of additional monitoring during the trial
- •4. Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2 (Modification of Diet in Renal Disease formula) or on dialysis at the screening visit. Patients entering the trial with eGFR 15-29 mL/min/1.73m2 will be undergo additional monitoring of renal function
- •- Because the MDRD formula is thought to cause significant bias for Japanese patients, the equation for Japanese patients is: 194 x serum creatinine (mg/dL) -1.094 x Age -0.287 x 0.739 (if female).
- •5. Any prior history of renal crisis
- •6. Sitting SBP < 95 mmHg at the screening visit
- •7. Sitting heart rate < 50 beats per minute (BPM) at the screening visit
- •8. Left ventricular ejection fraction < 40% prior to screening
- •9. Diagnosed PAH as determined by right heart catheterization
- •10. Pulmonary disease with FVC < 45% of predicted or DLCO (hemoglobin-corrected) < 40% of predicted at screening
- •11. Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization
- •12. Not permitted prior and concomitant medication (updated)
- •13. pregnant or breast feeding women
- •14. Women of childbearing potential not willing to use adequate contraception and not willing to agree to 4-weekly pregnancy testing from Visit 1 (first administration of study drug) onwards until 30 (+5) days after last study drug intake.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Blisibimod in IgA NephropathyEUCTR2014-001365-26-ESAnthera pharmaceuticals, Inc200
进行中（未招募）
1 期
Vedolizumab IV 300 mg in the Treatment of Chronic PouchitisEUCTR2015-003472-78-GBTakeda Development Centre Europe, Ltd.110
进行中（未招募）
1 期
A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host diseaseEUCTR2017-000538-78-PTIncyte Corporation436
进行中（未招募）
1 期
A Study of BLU-263 in patients with Indolent Systemic MastocytosisIndolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)MedDRA version: 27.0Level: PTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005173-28-ATBlueprint Medicines Corporation463
进行中（未招募）
1 期
A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host diseaseEUCTR2017-000538-78-ATIncyte Corporation436